Synklino
Synklino is an immunotoxin drug for cytomegalovirus in transplant recipients founded in 2017 by Thomas Kledal Ph.D., MBA , Mads Jeppesen Ph.D. and Mette Rosenkilde MD, Ph.D. .
3
Funding Rounds
$79.7m
Money raised
Overview
Synklino is an immunotoxin drug for cytomegalovirus in transplant recipients founded in 2017 by Thomas Kledal Ph.D., MBA , Mads Jeppesen Ph.D. and Mette Rosenkilde MD, Ph.D. .
- Website:
- Business model: B2B
- Social accounts: linkedin
| Name | Phone | Social networks | |
|---|---|---|---|
| Th**** Kl**** Ph**** MB* | - | - | - |
| Ma** Je****** Ph*** | - | - | - |
| Me*** Ro******** MD* Ph*** | - | - | - |
Funding
Funding series
Funding Series Analysis
The company Synklino has raised a total of $79.7m in funding over 3 rounds.
Key Insights:
- Synklino Series A round, June 2022: $31.7m
- Synklino June 2022 Series A Funding Round: $32m
- Synklino November 2021 Funding Round: $16m
Synklino Series A round, June 2022
$31.7m
Synklino June 2022 Series A Funding Round
$32m
Synklino November 2021 Funding Round
$16m
Industries
Synklino is active in the following industries: